The selection of a specific targeting ligand(s) to conjugate on the exterior of the Cur-nanomedicines mainly depends upon the type of biochemical target (e.g., FA-, transferrin- and/or CD44-receptors, or other genes and proteins) overexpressed on the surface of BC cells. Here, TF is linked to breast cancer.